&lt;p&gt;Quality of life in euthymic patients with unipolar major depressive disorder and bipolar disorder&lt;/p&gt;

Bo, Qijing; Tian, Lu; Li, Feng; Mao, Zhen; Wang, Zhimin; Ma, Xin; Wang, Chuanyue

doi:10.2147/ndt.s201567

Cited by 32 publications

(17 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This suggests that living in an assisted home incorporates social support and integration in a protected living situation, thereby positively influencing the patient’s QoL [ 67 ]. In a recent study from China in unipolar depressive patients, being married yielded a positive impact on all QoL domains [ 78 ], which was not supported by our findings. Cultural diversities as well as differences in the study populations did, however, allow only very limited comparability in this regard.…”

Section: Discussioncontrasting

confidence: 98%

Quality of life in patients with severe mental illness: a cross-sectional survey in an integrated outpatient health care model

et al. 2020

View full text Add to dashboard Cite

Purpose This study (a) assessed quality of life (QoL) in a patient sample with severe mental illness in an integrated psychiatric care (IC) programme in selected regions in Germany, (b) compared QoL among diagnostic groups and (c) identified socio-demographic, psychiatric anamnestic and clinical characteristics associated with QoL. Methods This cross-sectional study included severely mentally ill outpatients with substantial impairments in social functioning. Separate dimensions of QoL were assessed with the World Health Organisation’s generic 26-item quality of life (WHOQOL-BREF) instrument. Descriptive analyses and analyses of variance (ANOVAs) were conducted for the overall sample as well as for diagnostic group. Results A total of 953 patients fully completed the WHOQOL-BREF questionnaire. QoL in this sample was lower than in the general population (mean 34.1; 95% confidence interval (CI) 32.8 to 35.5), with the lowest QoL in unipolar depression patients (mean 30.5; 95% CI 28.9 to 32.2) and the highest in dementia patients (mean 53.0; 95% CI 47.5 to 58.5). Main psychiatric diagnosis, living situation (alone, partner/relatives, assisted), number of disease episodes, source of income, age and clinical global impression (CGI) scores were identified as potential predictors of QoL, but explained only a small part of the variation. Conclusion Aspects of health care that increase QoL despite the presence of a mental disorder are essential for severely mentally ill patients, as complete freedom from the disorder cannot be expected. QoL as a patient-centred outcome should be used as only one component among the recovery measures evaluating treatment outcomes in mental health care. Electronic supplementary material The online version of this article (10.1007/s11136-020-02470-0) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussioncontrasting

confidence: 98%

Quality of life in patients with severe mental illness: a cross-sectional survey in an integrated outpatient health care model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The demographic and clinical information of eligible subjects was collected with a self-designed case report form including career, gender, age, education level, previous health status, current medication status, history of addiction (tobacco, alcohol, coffee, drugs). The severity of symptoms was assessed by the HAMD-17 26 and the HAMA 27 , two reliable and valid instruments.…”

Section: Evaluation Instrumentsmentioning

confidence: 99%

Association between olfactory function and inhibition of emotional competing distractors in major depressive disorder

Wang

Jin

Wang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

We aimed to investigate the changes of olfaction of major depressive disorder (MDD) before and after medical treatment, and to preliminarily scrutinize the association between the olfactory function and the severity of depressive symptoms, response inhibition, and emotional responding. Forty-eight medicine-naïve MDD patients plus 33 healthy controls (HC) matched on gender, ages, and level of education, were recruited in the test group. The Chinese Smell Identification Test (CSIT), Self-reported Olfactory Scale (SROS), 17-item Hamilton Depression Rating Scale (HAMD-17), Hamilton Anxiety Rating Scale (HAMA), and mean reaction time/accuracy rate (ΔMRt) of emotional Stroop test were measured. The patients were assessed before the treatment (baseline) and 3 months after the treatment (follow-up). The data at the baseline level were measured then associated using multiple linear regression stepwise analysis. The MDD patients had lower scores of the CSIT and SROS and longer ΔMRt at baseline level compared to Hc while the ΔMRt of MDD patients remained longer after 3-month treatment (p's < 0.05). At the baseline level, the regression equation including age and ΔMRt of negative word-color congruent (NEG-C), was finally observed as follows: y(CSIT) = 10.676-0.063 × 1-0.002 × 2, [x 1 = the age(y), x 2 = the NEG-C (ms)]. The olfactory function of MDD appears to be correlated negatively with the age and the ΔMRT of negative stimuli before treatment. After the remission of MDD, the olfactory dysfunction was improved, which might be regarded as a responding phenotype of brain function of MDD rather than the emotional responding. Major depressive disorder (MDD) and olfaction disorder (OD) are both chronic diseases that affect human being's life quality 1. A systematic review on ten studies chosen for using the Sniffin' Sticks Test and the 40-item Smell Identification Test assessed to reveal the relationship between depression and OD. Results show that both of the olfactory threshold, olfactory discrimination, and olfactory identification were influenced by depression 2. Furthermore, symptoms of depression worsen with the severity of olfactory loss 3. It was demonstrated that olfactory bulbectomy, as a well-known method, could induce an animal model of depression in animal experiment 4. In depression-related brain areas including hippocampus, frontal cortex and hypothalamus, the turnover of serotonin and dopamine decreases in the olfactory bulbectomized rats 5. Similarly, in human studies, Cory et al. 6 found that patients with depression have decreased activities in the left medial orbitofrontal cortex (OFC) accompanied with the defect of the olfactory identification. However, Zucco et al. 7 argued that the changes mentioned above occur in patients with the MDD only, not with the mild or moderate depressive disorder. In the neural circuits involved in emotional processing 8 , these key structures such as amygdala, hippocampus, anterior cingulate cortex(ACC) and OFC, are the imperative functional regions of the human olfactory map...

show abstract

“…12 It is noteworthy that patients with BD commonly face residual mood symptoms, cognitive and functional impairment, psychosocial disability, and decreased quality of life even with the best treatment available. 13,14 BD has been suggested as a progressive condition, and the delay in diagnosis as well as inappropriate treatment can result in repeated mood episodes, persistent subthreshold symptoms, development of co-morbidities, and progression of the disease with cognitive impairment and functional decline. [15][16][17] The term ''neuroprogression'' has thus been conceptualized as the pathological rewiring of the brain that takes place in parallel with the functional and clinical deterioration that may occur in the course of BD; according to this concept, different stages of BD are associated with distinct neurobiological underpinnings.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Neurobiology of bipolar disorders: a review of genetic components, signaling pathways, biochemical changes, and neuroimaging findings

Scaini

Valvassori

Diaz

et al. 2020

Braz. J. Psychiatry

View full text Add to dashboard Cite

Bipolar disorder (BD) is a chronic mental illness characterized by changes in mood that alternate between mania and hypomania or between depression and mixed states, often associated with functional impairment. Although effective pharmacological and non-pharmacological treatments are available, several patients with BD remain symptomatic. The advance in the understanding of the neurobiology underlying BD could help in the identification of new therapeutic targets as well as biomarkers for early detection, prognosis, and response to treatment in BD. In this review, we discuss genetic, epigenetic, molecular, physiological and neuroimaging findings associated with the neurobiology of BD. Despite the advances in the pathophysiological knowledge of BD, the diagnosis and management of the disease are still essentially clinical. Given the complexity of the brain and the close relationship between environmental exposure and brain function, initiatives that incorporate genetic, epigenetic, molecular, physiological, clinical, environmental data, and brain imaging are necessary to produce information that can be translated into prevention and better outcomes for patients with BD.

show abstract

<p>Quality of life in euthymic patients with unipolar major depressive disorder and bipolar disorder</p>

Cited by 32 publications

References 39 publications

Quality of life in patients with severe mental illness: a cross-sectional survey in an integrated outpatient health care model

Quality of life in patients with severe mental illness: a cross-sectional survey in an integrated outpatient health care model

Association between olfactory function and inhibition of emotional competing distractors in major depressive disorder

Neurobiology of bipolar disorders: a review of genetic components, signaling pathways, biochemical changes, and neuroimaging findings

Contact Info

Product

Resources

About